Current Opinion in Infectious Diseases – February 2017 – Volume 30 – Issue 1 pp: v-vi,1-142

Current Opinion in Infectious Diseases
February 2017 – Volume 30 – Issue 1 pp: v-vi,1-142
http://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx

SEXUALLY TRANSMITTED DISEASES
Future prospects for new vaccines against sexually transmitted infections
Gottlieb, Sami L.; Johnston, Christine
Abstract
Purpose of review: This review provides an update on the need, development status, and important next steps for advancing development of vaccines against sexually transmitted infections (STIs), including herpes simplex virus (HSV), Neisseria gonorrhoeae (gonorrhea), Chlamydia trachomatis (chlamydia), and Treponema pallidum (syphilis).
Recent findings: Global estimates suggest that more than a million STIs are acquired every day, and many new and emerging challenges to STI control highlight the critical need for development of new STI vaccines. Several therapeutic HSV-2 vaccine candidates are in Phase I/II clinical trials, and one subunit vaccine has shown sustained reductions in genital lesions and viral shedding, providing hope that an effective HSV vaccine is on the horizon. The first vaccine candidate for genital chlamydia infection has entered Phase I trials, and several more are in the pipeline. Use of novel technological approaches will likely see viable vaccine candidates for gonorrhea and syphilis in the future. The global STI vaccine roadmap outlines key activities to further advance STI vaccine development.
Summary: Major progress is being made in addressing the large global unmet need for STI vaccines. With continued collaboration and support, these critically important vaccines for global sexual and reproductive health can become a reality.

Emerging Infectious Diseases – Volume 23, Number 1—January 2017

Emerging Infectious Diseases
Volume 23, Number 1—January 2017
http://wwwnc.cdc.gov/eid/

Perspective
A Framework for Modeling Emerging Diseases to Inform Management PDF Version [PDF – 424 KB – 6 pages]
R. E. Russell et al.
Abstract
The rapid emergence and reemergence of zoonotic diseases requires the ability to rapidly evaluate and implement optimal management decisions. Actions to control or mitigate the effects of emerging pathogens are commonly delayed because of uncertainty in the estimates and the predicted outcomes of the control tactics. The development of models that describe the best-known information regarding the disease system at the early stages of disease emergence is an essential step for optimal decision-making. Models can predict the potential effects of the pathogen, provide guidance for assessing the likelihood of success of different proposed management actions, quantify the uncertainty surrounding the choice of the optimal decision, and highlight critical areas for immediate research. We demonstrate how to develop models that can be used as a part of a decision-making framework to determine the likelihood of success of different management actions given current knowledge.

Emerging Infectious Diseases – Volume 23, Number 1—January 2017  

Emerging Infectious Diseases
Volume 23, Number 1—January 2017
http://wwwnc.cdc.gov/eid/

Research
Oral Cholera Vaccine Coverage during an Outbreak and Humanitarian Crisis, Iraq, 2015 PDF Version [PDF – 757 KB – 8 pages]
E. Lam et al.
Abstract
During November–December 2015, as part of the 2015 cholera outbreak response in Iraq, the Iraqi Ministry of Health targeted ≈255,000 displaced persons >1 year of age with 2 doses of oral cholera vaccine (OCV). All persons who received vaccines were living in selected refugee camps, internally displaced persons camps, and collective centers. We conducted a multistage cluster survey to obtain OCV coverage estimates in 10 governorates that were targeted during the campaign. In total, 1,226 household and 5,007 individual interviews were conducted. Overall, 2-dose OCV coverage in the targeted camps was 87% (95% CI 85%–89%). Two-dose OCV coverage in the 3 northern governorates (91%; 95% CI 87%–94%) was higher than that in the 7 southern and central governorates (80%; 95% CI 77%–82%). The experience in Iraq demonstrates that OCV campaigns can be successfully implemented as part of a comprehensive response to cholera outbreaks among high-risk populations in conflict settings.

Global Health: Science and Practice (GHSP) – December 2016 | Volume 4 | Issue 4

Global Health: Science and Practice (GHSP)
December 2016 | Volume 4 | Issue 4
http://www.ghspjournal.org/content/current

VIEWPOINTS
Improving the Safety and Security of Those Engaged in Global Health Traveling Abroad
We need to improve the safety and security of global health students, faculty, residents, and workers who travel abroad, particularly those affiliated with smaller organizations or educational programs that lack resources and protocols. We offer a checklist covering 6 core elements: (1) institutional commitment, (2) trainee and faculty participation, (3) safety and security assessment and analysis, (4) risk and hazard prevention, (5) safety training, and (6) program evaluation.
Ranit Mishori, Andrew Eastman, Jessica Evert
Glob Health Sci Pract 2016;4(4):522-528. http://dx.doi.org/10.9745/GHSP-D-16-00203

Global Health: Science and Practice – (GHSP) December 2016 | Volume 4 | Issue 4

Global Health: Science and Practice (GHSP)
December 2016 | Volume 4 | Issue 4
http://www.ghspjournal.org/content/current

VIEWPOINTS
Social Mobilization and Community Engagement Central to the Ebola Response in West Africa: Lessons for Future Public Health Emergencies
Key lessons for the crucial components of social mobilization and community engagement in this context:
:: Invest in trusted local community members to facilitate community entrance and engagement.
:: Use key communication networks and channels with wide reach and relevance to the community, such as radio in low-resource settings or faith-based organizations.
:: Invest in strategic partnerships to tap relevant capacities and resources.
: Support a network of communication professionals who can deploy rapidly for lengthy periods.
Balance centralized mechanisms to promote consistency and quality with decentralized programming for flexibility and adaptation to local needs.
:: Evolve communication approaches and messaging over time with the changing outbreak patterns, e.g., from halting disease transmission to integration and support of survivors.
:: Establish clear communication indicators and analyze and share data in real time.
Amaya M Gillespie, Rafael Obregon, Rania El Asawi, Catherine Richey, Erma Manoncourt, Kshiitij Joshi, Savita Naqvi, Ade Pouye, Naqibullah Safi, Ketan Chitnis, Sabeeha Quereshi
Glob Health Sci Pract 2016;4(4):626-646. http://dx.doi.org/10.9745/GHSP-D-16-00226
ABSTRACT
Following the World Health Organization (WHO) declaration of a Public Health Emergency of International Concern regarding the Ebola outbreak in West Africa in July 2014, UNICEF was asked to co-lead, in coordination with WHO and the ministries of health of affected countries, the communication and social mobilization component—which UNICEF refers to as communication for development (C4D)—of the Ebola response. For the first time in an emergency setting, C4D was formally incorporated into each country’s national response, alongside more typical components such as supplies and logistics, surveillance, and clinical care. This article describes the lessons learned about social mobilization and community engagement in the emergency response to the Ebola outbreak, with a particular focus on UNICEF’s C4D work in Guinea, Liberia, and Sierra Leone. The lessons emerged through an assessment conducted by UNICEF using 4 methods: a literature review of key documents, meeting reports, and other articles; structured discussions conducted in June 2015 and October 2015 with UNICEF and civil society experts; an electronic survey, launched in October and November 2015, with staff from government, the UN, or any partner organization who worked on Ebola (N = 53); and key informant interviews (N = 5). After triangulating the findings from all data sources, we distilled lessons under 7 major domains: (1) strategy and decentralization: develop a comprehensive C4D strategy with communities at the center and decentralized programming to facilitate flexibility and adaptation to the local context; (2) coordination: establish C4D leadership with the necessary authority to coordinate between partners and enforce use of standard operating procedures as a central coordination and quality assurance tool; (3) entering and engaging communities: invest in key communication channels (such as radio) and trusted local community members; (4) messaging: adapt messages and strategies continually as patterns of the epidemic change over time; (5) partnerships: invest in strategic partnerships with community, religious leaders, journalists, radio stations, and partner organizations; (6) capacity building: support a network of local and international professionals with capacity for C4D who can be deployed rapidly; (7) data and performance monitoring: establish clear C4D process and impact indicators and strive for real-time data analysis and rapid feedback to communities and authorities to inform decision making. Ultimately, communication, community engagement, and social mobilization need to be formally placed within the global humanitarian response architecture with proper funding to effectively support future public health.

Globalization and Health

Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 7 January 2017]

Review
The link between the West African Ebola outbreak and health systems in Guinea, Liberia and Sierra Leone: a systematic review
Haitham Shoman, Emilie Karafillakis and Salman Rawaf
Published on: 4 January 2017
Abstract
Background
An Ebola outbreak started in December 2013 in Guinea and spread to Liberia and Sierra Leone in 2014. The health systems in place in the three countries lacked the infrastructure and the preparation to respond to the outbreak quickly and the World Health Organisation (WHO) declared a public health emergency of international concern on August 8 2014.
Objective
The aim of this study was to determine the effects of health systems’ organisation and performance on the West African Ebola outbreak in Guinea, Liberia and Sierra Leone and lessons learned. The WHO health system building blocks were used to evaluate the performance of the health systems in these countries.
Methods
A systematic review of articles published from inception until July 2015 was conducted following the PRISMA guidelines. Electronic databases including Medline, Embase, Global Health, and the Cochrane library were searched for relevant literature. Grey literature was also searched through Google Scholar and Scopus. Articles were exported and selected based on a set of inclusion and exclusion criteria. Data was then extracted into a spreadsheet and a descriptive analysis was performed. Each study was critically appraised using the Crowe Critical Appraisal Tool. The review was supplemented with expert interviews where participants were identified from reference lists and using the snowball method.
Findings
Thirteen articles were included in the study and six experts from different organisations were interviewed. Findings were analysed based on the WHO health system building blocks. Shortage of health workforce had an important effect on the control of Ebola but also suffered the most from the outbreak. This was followed by information and research, medical products and technologies, health financing and leadership and governance. Poor surveillance and lack of proper communication also contributed to the outbreak. Lack of available funds jeopardised payments and purchase of essential resources and medicines. Leadership and governance had least findings but an overarching consensus that they would have helped prompt response, adequate coordination and management of resources.
Conclusion
Ensuring an adequate and efficient health workforce is of the utmost importance to ensure a strong health system and a quick response to new outbreaks. Adequate service delivery results from a collective success of the other blocks. Health financing and its management is crucial to ensure availability of medical products, fund payments to staff and purchase necessary equipment. However, leadership and governance needs to be rigorously explored on their main defects to control the outbreak.

Health Research Policy and Systems

Health Research Policy and Systems
http://www.health-policy-systems.com/content
[Accessed 7 January 2017]

Editorial
Building health research systems: WHO is generating global perspectives, and who’s celebrating national successes?
Stephen R. Hanney and Miguel A. González-Block
Published on: 28 December 2016
Abstract
In 2016, England’s National Institute for Health Research (NIHR) celebrated its tenth anniversary as an innovative national health research system with a focus on meeting patients’ needs. This provides a good opportunity to reflect on how the creation of the NIHR has greatly enhanced important work, started in 1991, to develop a health research system in England that is embedded in the National Health Service.
In 2004, WHO identified a range of functions that a national health research system should undertake to improve the health of populations. Health Research Policy and Systems (HRPS) has taken particular interest in the pioneering developments in the English health research system, where the comprehensive approach has covered most, if not all, of the functions identified by WHO. Furthermore, several significant recent developments in thinking about health research are relevant for the NIHR and have informed accounts of its achievements. These include recognition of the need to combat waste in health research, which had been identified as a global problem in successive papers in the Lancet, and an increasing emphasis on demonstrating impact. Here, pioneering evaluation of United Kingdom research, conducted through the impact case studies of the Research Excellence Framework, is particularly important. Analyses informed by these and other approaches identified many aspects of NIHR’s progress in combating waste, building and sustaining research capacity, creating centres of research excellence linked to leading healthcare institutions, developing research networks, involving patients and others in identifying research needs, and producing and adopting research findings that are improving health outcomes.
The NIHR’s overall success, and an analysis of the remaining problems, might have lessons for other systems, notwithstanding important advances in many countries, as described in papers in HRPS and elsewhere. WHO’s recently established Global Observatory for Health Research and Development provides an opportunity to promote some of these lessons. To inform its work, the Observatory is sponsoring a thematic series of papers in HRPS focusing on health research issues such as funding flows, priority setting, capacity building, utilisation and equity. While important papers on these have been published, this series is still open to new submissions.

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 12, Issue 12, 2016
http://www.tandfonline.com/toc/khvi20/current

Review article
Comparison of dual influenza and pneumococcal polysaccharide vaccination with influenza vaccination alone for preventing pneumonia and reducing mortality among the elderly: A meta-analysis
Pages: 3056-3064
Published online: 14 Sep 2016
Yan-Yang Zhang, Xue-Feng Tang, Chang-Hui Du, Bin-Bing Wang, Zhen-Wang Bi & Bi-Rong Dong

Review
Influenza immunization during pregnancy: Benefits for mother and infant
Pages: 3065-3071
Published online: 05 Aug 2016
Isaac G. Sakala, Yoshikazu Honda-Okubo, Johnson Fung & Nikolai Petrovsky Director

Commentary
The safety of maternal immunization
Pages: 3132-3136
Published online: 19 Aug 2016
Annette K. Regan

Research Paper
How do parents and pediatricians arrive at the decision to immunize their children in the private sector? Insights from a qualitative study on rotavirus vaccination across select Indian cities
Pages: 3139-3145
Published online: 23 Nov 2016
Mathew Sunil George, Preeti Negandhi, Habib Hassan Farooqui, Anjali Sharma & Sanjay Zodpey

Reviews
Community pharmacies as sites of adult vaccination: A systematic review
Pages: 3146-3159
Published online: 15 Aug 2016
Randall C. Burson, Alison M. Buttenheim, Allison Armstrong & Kristen A. Feemster

Infectious Agents and Cancer

Infectious Agents and Cancer

[Accessed 7 January 2017]

Research Article

Multiple HPV infections in female sex workers in Western Kenya: implications for prophylactic vaccines within this sub population
Whilst the imputed role of High Risk (HR) HPV infection in the development of cervical lesions and cancer has been established, the high number of HPV genotypes that Female Sex workers (FSW) harbour warrants that the synergistic effects of potential HR (pHR) and HR HPV genotypes be elucidated to assess the potential impact of prophylactic vaccines. This population in Kenya also harbours a number of other vaginal infections and STIs, including bacterial vaginosis (BV), trichomonas vaginalis (TV) and candida spp.
Sonia Menon, Davy van den Broeck, Rodolfo Rossi, Emilomo Ogbe and Hillary Mabeya
Infectious Agents and Cancer 2017 12:2
Published on: 6 January 2017

International Journal of Infectious Diseases – December 2016 Volume 53, p1-68

International Journal of Infectious Diseases
December 2016 Volume 53, p1-68
http://www.ijidonline.com/issue/S1201-9712(16)X0011-2
Reviews
Drivers of earlier infectious disease outbreak detection: a systematic literature review
Lindsay Steele, Emma Orefuwa, Petra Dickmann
p15–20
Published online: October 21, 2016
Highlights
Early detection of infectious disease outbreaks can lead to a decreased impact on populations. Numerous approaches to the earlier detection of outbreaks exist, and methods have been developed to measure progress on timeliness. Understanding why these surveillance approaches work and do not work will elucidate key drivers of early detection, and could guide interventions to achieve earlier detection. Without clarity about necessary conditions for earlier detection and their influencing factors, attempts to improve surveillance will be ad hoc and unsystematic.
This systematic literature review revealed that despite significant investment in early outbreak detection, there is very little evidence with respect to factors that influence earlier detection. More research is needed to guide intervention planning.

International Journal of Infectious Diseases – December 2016 Volume 53, p1-68

International Journal of Infectious Diseases
December 2016 Volume 53, p1-68
http://www.ijidonline.com/issue/S1201-9712(16)X0011-2

Original Reports
Clinical profile and containment of the Ebola virus disease outbreak in two large West African cities, Nigeria, July–September 2014
Chima Ohuabunwo, Celestine Ameh, Oyin Oduyebo, Anthony Ahumibe, Bamidele Mutiu, Adebola Olayinka, Wasiu Gbadamosi, Erika Garcia, Carolina Nanclares, Wale Famiyesin, Abdulaziz Mohammed, Patrick Nguku, Richard I. Koko, Joshua Obasanya, Durojaye Adebayo, Yemi Gbadegesin, Oni Idigbe, Olukayode Oguntimehin, Sara Nyanti, Charles Nzuki, Ismail Abdus-Salam, Joseph Adeyemi, Nnanna Onyekwere, Emmanuel Musa, David Brett-Major, Faisal Shuaib, Abdulsalami Nasidi
p23–29
Published online: August 27, 2016

JAMA Pediatrics – January 1, 2017, Vol 171, No. 1, Pages 3-100

JAMA Pediatrics
January 1, 2017, Vol 171, No. 1, Pages 3-100
http://archpedi.jamanetwork.com/issue.aspx

Original Investigation
Association Between Influenza Infection and Vaccination During Pregnancy and Risk of Autism Spectrum Disorder
Ousseny Zerbo, PhD; Yinge Qian, MS; Cathleen Yoshida, MA; et al.
online only
JAMA Pediatr. 2017;171(1):e163609. doi:10.1001/jamapediatrics.2016.3609
Key Points
Question  Is there an association between maternal influenza infection and vaccination and autism risk?
Findings  In a cohort study of 196,929 children, of whom 3103 had austism spectrum disorder, maternal influenza infection during pregnancy was not associated with increased autism risk. There was a suggestion of increased risk of autism spectrum disorders among children whose mothers received an influenza vaccination during their first trimester, but the association was statistically insignificant after adjusting for multiple comparisons, indicating that the finding could be due to chance.
Meaning  Our findings do not call for vaccine policy or practice changes but do suggest the need for additional studies.
Abstract
Importance
Maternal infections and fever during pregnancy are associated with increased risk for autism spectrum disorders (ASDs). To our knowledge, no study has investigated the association between influenza vaccination during pregnancy and ASD.
Objective
To investigate the association between influenza infection and vaccination during pregnancy and ASD risk.
Design, Setting, and Participants
This cohort study included 196 929 children born at Kaiser Permanente Northern California from January 1, 2000 to December 31, 2010, at a gestational age of at least 24 weeks.
Exposures
Data on maternal influenza infection and vaccination from conception date to delivery date, obtained from Kaiser Permanente Northern California inpatient and outpatient databases. Influenza infection was defined by the International Classification of Diseases, Ninth Revision, Clinical Modification codes or positive influenza laboratory test results.
Main Outcomes and Measures
Clinical diagnoses of ASDs identified by International Classification of Diseases, Ninth Revision, Clinical Modification codes 299.0, 299.8, or 299.9 recorded in Kaiser Permanente Northern California electronic medical records on at least 2 occasions any time from birth through June 2015.
Results
Within this cohort of 196 929 children, influenza was diagnosed in 1400 (0.7%) mothers and 45 231 (23%) received an influenza vaccination during pregnancy. The mean (SD) ages of vaccinated and unvaccinated women were 31.6 (5.2) and 30.4 (5.6) years, respectively. A total number of 3101 (1.6%) children were diagnosed with ASD. After adjusting for covariates, we found that maternal influenza infection (adjusted hazard ratio, 1.04; 95% CI, 0.68-1.58) or influenza vaccination (adjusted hazard ratio, 1.10; 95% CI, 1.00-1.21) anytime during pregnancy was not associated with increased ASD risk. In trimester-specific analyses, first-trimester influenza vaccination was the only period associated with increased ASD risk (adjusted hazard ratio, 1.20; 95% CI, 1.04-1.39). However, this association could be due to chance (P = 0.1) if Bonferroni corrected for the multiplicity of hypotheses tested (n = 8). Maternal influenza vaccination in the second or third trimester was not associated with increased ASD risk.
Conclusions and Relevance
There was no association between maternal influenza infection anytime during pregnancy and increased ASD risk. There was a suggestion of increased ASD risk among children whose mothers received an influenza vaccination in their first trimester, but the association was not statistically significant after adjusting for multiple comparisons, indicating that the finding could be due to chance. These findings do not call for changes in vaccine policy or practice, but do suggest the need for additional studies on maternal influenza vaccination and autism.

JAMA Pediatrics – January 1, 2017, Vol 171, No. 1, Pages 3-100

JAMA Pediatrics
January 1, 2017, Vol 171, No. 1, Pages 3-100
http://archpedi.jamanetwork.com/issue.aspx

Viewpoint
The Complexities of Conducting Research on Child Trafficking
Jonathan Todres, JD; Leslie E. Wolf, JD, MPH
JAMA Pediatr. 2017;171(1):9-10. doi:10.1001/jamapediatrics.2016.3532
Child trafficking is a significant public health problem in the United States and globally.1 Despite substantial efforts to respond to human trafficking over the past 15 years, there is still relatively little known about its prevalence and effective ways to prevent, identify, and respond to it.2

Journal of Epidemiology & Community Health – January 2017, Volume 71, Issue 1

Journal of Epidemiology & Community Health
January 2017, Volume 71, Issue 1
http://jech.bmj.com/content/current
Review
Interventions to reduce inequalities in vaccine uptake in children and adolescents aged Tim Crocker-Buque, Michael Edelstein, Sandra Mounier-Jack
J Epidemiol Community Health 2017;71:87-97 Published Online First: 17 August 2016 doi:10.1136/jech-2016-207572
Abstract
Background
In high-income countries, substantial differences exist in vaccine uptake relating to socioeconomic status, gender, ethnic group, geographic location and religious belief. This paper updates a 2009 systematic review on effective interventions to decrease vaccine uptake inequalities in light of new technologies applied to vaccination and new vaccine programmes (eg, human papillomavirus in adolescents).
Methods
We searched MEDLINE, Embase, ASSIA, The Campbell Collaboration, CINAHL, The Cochrane Database of Systematic Reviews, Eppi Centre, Eric and PsychINFO for intervention, cohort or ecological studies conducted at primary/community care level in children and young people from birth to 19 years in OECD countries, with vaccine uptake or coverage as outcomes, published between 2008 and 2015.
Results
The 41 included studies evaluated complex multicomponent interventions (n=16), reminder/recall systems (n=18), outreach programmes (n=3) or computer-based interventions (n=2). Complex, locally designed interventions demonstrated the best evidence for effectiveness in reducing inequalities in deprived, urban, ethnically diverse communities. There is some evidence that postal and telephone reminders are effective, however, evidence remains mixed for text-message reminders, although these may be more effective in adolescents. Interventions that escalated in intensity appeared particularly effective. Computer-based interventions were not effective. Few studies targeted an inequality specifically, although several reported differential effects by the ethnic group.
Conclusions
Locally designed, multicomponent interventions should be used in urban, ethnically diverse, deprived populations. Some evidence is emerging for text-message reminders, particularly in adolescents. Further research should be conducted in the UK and Europe with a focus on reducing specific inequalities.

Journal of Infectious Diseases – Volume 214 Issue 12 December 15, 2016

Journal of Infectious Diseases
Volume 214 Issue 12 December 15, 2016
http://jid.oxfordjournals.org/content/current

VIRUSES
Risk of Delayed Human Papillomavirus Vaccination in Inner-City Adolescent Women
J Infect Dis. (2016) 214 (12): 1952-1960 doi:10.1093/infdis/jiw486
Nicolas F. Schlecht, Angela Diaz, Viswanathan Shankar, Arnold H. Szporn, Maoxin Wu,
Anne Nucci-Sack, Ken Peake, Howard D. Strickler, and Robert D. Burk
Abstract
Background.
Uptake of human papillomavirus (HPV) vaccine in the United States is slow, and the effectiveness of the vaccine has not been assessed in high-risk adolescent populations.
Methods.
We conducted a longitudinal study of 1139 sexually active, inner-city adolescent women receiving the 3-dose quadrivalent (4vHPV) vaccine. Cervical and anal specimens collected semiannually were tested using an L1-specific polymerase chain reaction assay. Postvaccination incidence of 4vHPV vaccine and nonvaccine HPV types, and risk of cervical cytological abnormalities, were assessed in relation to time to completion of all 3 vaccine doses.
Results.
Compared to vaccine naive women at enrollment, vaccinated women had significantly lower incidence rate ratios of cervical infection with HPV6/11/16/18 (0.2; 95% confidence interval [CI], .1–.4) and the related types HPV31 and HPV45 (0.4 [95% CI, .2–1.0] and 0.3 [95% CI, .1–.6], respectively), as well as significantly lower incidence rate ratios of anal infection with HPV6/11/16/18 (0.4; 95% CI, .2–.7). Notably, we observed higher risks of cervical HPV6/11/16/18 infection (hazards ratio [HR], 2.9; 95% CI, 1.0–8.0) and associated cytological abnormalities (HR, 4.5; 95% CI, .7–26.0) among women immunized at ≥15 years of age who took ≥12 months (vs Conclusions.
Among adolescents immunized at ≥15 years of age, a longer time to complete the 3-dose schedule was associated with an increased risk of anogenital HPV6/11/16/18 infection and an increased incidence of associated cervical cytological abnormalities.

Journal of Infectious Diseases – Volume 214 Issue 12 December 15, 2016

Journal of Infectious Diseases
Volume 214 Issue 12 December 15, 2016
http://jid.oxfordjournals.org/content/current

Measles Outbreak Among Previously Immunized Healthcare Workers, the Netherlands, 2014
J Infect Dis. (2016) 214 (12): 1980-1986 doi:10.1093/infdis/jiw480
Susan J. M. Hahné, Laura M. Nic Lochlainn, Nathalie D. van Burgel, Jeroen Kerkhof, Jussi Sane,
Kioe Bing Yap, and Rob S. van Binnendijk

Journal of Medical Ethics – January 2017, Volume 43, Issue 1

Journal of Medical Ethics
January 2017, Volume 43, Issue 1
http://jme.bmj.com/content/current

Law, ethics and medicine
Paper: Towards a European code of medical ethics. Ethical and legal issues
Sara Patuzzo, Elisabetta Pulice
J Med Ethics 2017;43:41-46 Published Online First: 8 October 2016 doi:10.1136/medethics-2015-102963
Abstract
The feasibility of a common European code of medical ethics is discussed, with consideration and evaluation of the difficulties such a project is going to face, from both the legal and ethical points of view. On the one hand, the analysis will underline the limits of a common European code of medical ethics as an instrument for harmonising national professional rules in the European context; on the other hand, we will highlight some of the potentials of this project, which could be increased and strengthened through a proper rulemaking process and through adequate and careful choice of content. We will also stress specific elements and devices that should be taken into consideration during the establishment of the code, from both procedural and content perspectives. Regarding methodological issues, the limits and potentialities of a common European code of medical ethics will be analysed from an ethical point of view and then from a legal perspective. The aim of this paper is to clarify the framework for the potential but controversial role of the code in the European context, showing the difficulties in enforcing and harmonising national ethical rules into a European code of medical ethics.

Journal of Medical Microbiology – Volume 65, Issue 12, December 2016

Journal of Medical Microbiology
Volume 65, Issue 12, December 2016
http://jmm.microbiologyresearch.org/content/journal/jmm/65/12

Review
Prevention of herpes zoster and its complications: from the clinic to the real-life experience with the vaccine
Gabutti Giovanni, Valente Nicoletta, Kuhdari Parvanè, Lupi Silvia, Stefanati Armando
J. Med. Microbiol., December 2016 65: 1363-1369, doi: 10.1099/jmm.0.000386
Abstract
The herpes zoster is an acute viral illness characterized by a vesicular rash of unilateral distribution, which can eventually cause severe complications, such as post-herpetic neuralgia, ophthalmic zoster, stroke or other neurological complications. In Europe, an incidence of between 2.0 and 4.6 cases per 1000 person-years is estimated, with an increase after 50 years of age. Currently, the therapeutic options for are only partially effective in limiting the acute phase, while the management of complications is frequently complex and not satisfactory. The overall burden of the disease and the elevated costs associated with diagnosis and clinical and therapeutic management led to the development of a new preventive approach through a live attenuated virus vaccine. The vaccine now available decreases the incidence of the disease, post-herpetic neuralgia and the burden of illness. Moreover, the vaccine is safe and well tolerated and it seems to confer long-term protection. Based on the clinical results and evidence provided by the Health Technology Assessment, several countries introduced immunization although with different recommendations and methods of funding.

The Lancet – Jan 07, 2017 Volume 389 Number 10064 p1-126 e1

The Lancet
Jan 07, 2017 Volume 389 Number 10064 p1-126 e1
http://www.thelancet.com/journals/lancet/issue/current

Series
Advancing Early Childhood Development: from Science to Scale
Early childhood development coming of age: science through the life course
Maureen M Black, Susan P Walker, Lia C H Fernald, Christopher T Andersen, Ann M DiGirolamo, Chunling Lu, Dana C McCoy, Günther Fink, Yusra R Shawar, Jeremy Shiffman, Amanda E Devercelli, Quentin T Wodon, Emily Vargas-Barón, Sally Grantham-McGregor, Lancet Early Childhood Development Series Steering Committee

Advancing Early Childhood Development: from Science to Scale
Nurturing care: promoting early childhood development
Pia R Britto, Stephen J Lye, Kerrie Proulx, Aisha K Yousafzai, Stephen G Matthews, Tyler Vaivada, Rafael Perez-Escamilla, Nirmala Rao, Patrick Ip, Lia C H Fernald, Harriet MacMillan, Mark Hanson, Theodore D Wachs, Haogen Yao, Hirokazu Yoshikawa, Adrian Cerezo, James F Leckman, Zulfiqar A Bhutta, Early Childhood Development Interventions Review Group, for the Lancet Early Childhood Development Series Steering Committee

Advancing Early Childhood Development: from Science to Scale
Investing in the foundation of sustainable development: pathways to scale up for early childhood development
Linda M Richter, Bernadette Daelmans, Joan Lombardi, Jody Heymann, Florencia Lopez Boo, Jere R Behrman, Chunling Lu, Jane E Lucas, Rafael Perez-Escamilla, Tarun Dua, Zulfiqar A Bhutta, Karin Stenberg, Paul Gertler, Gary L Darmstadt, Paper 3 Working Group and the Lancet Early Childhood Development Series Steering Committee

Health Policy
Generation of global political priority for early childhood development: the challenges of framing and governance
Yusra Ribhi Shawar, Jeremy Shiffman

Lancet Global Health – Jan 2017 Volume 5 Number 1 e1-e114

Lancet Global Health
Jan 2017 Volume 5 Number 1 e1-e114
http://www.thelancet.com/journals/langlo/issue/current

Editorial
Precision global health: beyond prevention and control
The Lancet Global Health
As we step into 2017 and look back at the past year, Zika undoubtedly stands out. 2016 saw the rise and fall of the epidemic in the Americas and worldwide spread of cases, until WHO declared on Nov 18 that the virus and associated consequences no longer constituted a Public Health Emergency of International Concern, but represented a “significant enduring public health challenge requiring intense action”. As such, Zika joined other “enduring public health challenges” to which “intense action” has been directed for a long time, particularly other communicable and vector-borne diseases, on the list of health priorities. With Zika we are almost in uncharted territory: the heterogeneity in the natural history of the disease and transmission pathways still blur the picture of what is likely to be a long-term global health issue. Yet with some other diseases, a wealth of knowledge and seemingly defined course of action have not enabled us to close the chapter.

Much has been achieved on malaria, for example, but progress is fragile and we are still scrambling in areas where the burden persists despite decades of interventions. One major concern is resistance to pyrethroids used in long-lasting insecticidal nets (LLIN), a cornerstone of malaria control. During the 65th American Society for Tropical Medicine and Hygiene (ASTMH) meeting in Atlanta in November, WHO released the results of a study that shows that LLINs provide protection against malaria even in areas with resistance. However, in this issue of The Lancet Global Health, Laura Steinhardt and colleagues report contrasting results of a case control study in Haiti that raises doubts on the usefulness of nets in a low transmission setting, hinting that their mass distribution is not a panacea everywhere. In fact, a session at ASTMH explored key knowledge gaps in malaria interventions and raised thought-provoking questions on what is needed to finally get rid of the disease, given issues of resistance, uncertainties about newer strategies such as seasonal malaria chemoprevention or intermittent preventive treatment for pregnant women, and potential impact of the RTS,S vaccine. As highlighted during the session, there is no silver bullet, and success may only be found by putting multiple axes of pressure on the vector through combinations of interventions. The trick is figuring out what combination works in what setting, and that seems to be the next big question around malaria elimination: how do we develop decision tools to tailor interventions to a set of biological and social determinants—in other words, how do we move on to a more customised approach, through what could be called “precision global health”?

The idea of a “precision” approach to global health is not limited to malaria. Prevention strategies against soil-transmitted helminths (STH) for example have included water, sanitation, and hygiene interventions and mass drug administration, another imperfect and controversial intervention as highlighted in an Article by Vivian Welch and colleagues and two Comments in this issue. In their network meta-analysis, Welch and colleagues found little to no effect of mass deworming on children’s growth, cognition, and school attendance. Eliminating the last pockets of STH incidence and prevalence will therefore require another precision approach, maybe one that combines controlling the parasites with working on more distal determinants of infection such as poverty.

A tailored approach will also help in reaching broader global health targets. The decrease in child mortality during the Millennium Development Goals era has been real but insufficient, and unequal. In some areas progress could be accelerated with more refined targeting of causes of death. Knowing where to target interventions to reduce mortality, by analysing the variability in the distribution of health outcomes for different causes would optimise efforts to reduce child mortality. A study by Marshall Burke and colleagues published in the last issue provides such valuable input, by identifying subnational mortality hotspots across sub-Saharan Africa in which the mortality decline is not on target to reach the Sustainable Development Goals (SDG) by 2030, as well as potential drivers for the difference in mortality. Spatial analyses of this kind provide crucial granular information—in line with a precision approach to global health—that could contribute to the progress towards the SDGs.

So beyond the essential steps of event surveillance and case management, on which the prevention and control of diseases are based, if we are to truly advance health and eliminate diseases, a case can be made for a tailored approach and the advent of precision-style global health.

Lancet Global Health – Jan 2017 Volume 5 Number 1 e1-e114

Lancet Global Health
Jan 2017 Volume 5 Number 1 e1-e114
http://www.thelancet.com/journals/langlo/issue/current

Articles
Indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review and meta-analysis
Tinevimbo Shiri, Samik Datta, Jason Madan, Alexander Tsertsvadze, Pamela Royle, Matt J Keeling, Noel D McCarthy, Stavros Petrou

The Lancet Infectious Diseases – Jan 2017 Volume 17 Number 1 p1-116 e1-e29

The Lancet Infectious Diseases
Jan 2017 Volume 17 Number 1 p1-116 e1-e29
http://www.thelancet.com/journals/laninf/issue/current

Articles
Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial
Helen S Marshall, Peter C Richmond, Johannes Beeslaar, Qin Jiang, Kathrin U Jansen, Maria Garcés-Sánchez, Federico Martinón-Torres, Leszek Szenborn, Jacek Wysocki, Joseph Eiden, Shannon L Harris, Thomas R Jones, Su-San Lee, John L Perez, 6108A12001 Study Investigators

Lancet Infectious Diseases – Jan 2017 Volume 17 Number 1 p1-116 e1-e29

The Lancet Infectious Diseases
Jan 2017 Volume 17 Number 1 p1-116 e1-e29
http://www.thelancet.com/journals/laninf/issue/current

Articles
Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study
Eric P F Chow, Dorothy A Machalek, Sepehr N Tabrizi, Jennifer A Danielewski, Glenda Fehler, Catriona S Bradshaw, Suzanne M Garland, Marcus Y Chen, Christopher K Fairley

Nature Reviews Immunology – January 2017 Vol 17 No 1

Nature Reviews Immunology
January 2017 Vol 17 No 1
http://www.nature.com/nri/journal/v16/n12/index.html

Reviews
Human immune system variation
Petter Brodin & Mark M. Davis
p21 | doi:10.1038/nri.2016.125
Abstract
The human immune system is highly variable between individuals but relatively stable over time within a given person. Recent conceptual and technological advances have enabled systems immunology analyses, which reveal the composition of immune cells and proteins in populations of healthy individuals. The range of variation and some specific influences that shape an individual’s immune system is now becoming clearer. Human immune systems vary as a consequence of heritable and non-heritable influences, but symbiotic and pathogenic microbes and other non-heritable influences explain most of this variation. Understanding when and how such influences shape the human immune system is key for defining metrics of immunological health and understanding the risk of immune-mediated and infectious diseases.

New England Journal of Medicine – January 5, 2017 Vol. 376 No. 1

New England Journal of Medicine
January 5, 2017  Vol. 376 No. 1
http://www.nejm.org/toc/nejm/medical-journal

Review Article
The Changing Face of Clinical Trials
Jeffrey M. Drazen, M.D., David P. Harrington, Ph.D., John J.V. McMurray, M.D., James H. Ware, Ph.D., Janet Woodcock, M.D., Editors
The Large Pharmaceutical Company Perspective
Michael Rosenblatt, M.D.
N Engl J Med 2017; 376:52-60 January 5, 2017 DOI: 10.1056/NEJMra1510069
Large pharmaceutical companies conduct clinical trials to evaluate efficacy and identify safety issues for candidate drugs as effectively, efficiently, and expeditiously as possible, while addressing simultaneously the requirements of regulatory authorities across the globe. To put the fewest people at risk and to learn the most, these trials often are configured to provide evidence for health care providers, regulatory approval, and reimbursement from health agencies. Because there are so many unknowns, pharmaceutical research and development is a high-risk business with the highest failure rate for new product candidates of any industry.

Pediatrics – January 2017, VOLUME 139 / ISSUE

Pediatrics
January 2017, VOLUME 139 / ISSUE
http://pediatrics.aappublications.org/content/139/1?current-issue=y

Articles
Safety of Quadrivalent Meningococcal Conjugate Vaccine in 11- to 21-Year-Olds
Hung-Fu Tseng, Lina S. Sy, Bradley K. Ackerson, Rulin C. Hechter, Sara Y. Tartof, Mendel Haag, Jeffrey M. Slezak, Yi Luo, Christine A. Fischetti, Harp S. Takhar, Yan Miao, Marianne Cunnington, Zendi Solano, Steven J. Jacobsen
Pediatrics Jan 2017, 139 (1) e20162084; DOI: 10.1542/peds.2016-2084

PharmacoEconomics – Volume 35, Issue 1, January 2017

PharmacoEconomics
Volume 35, Issue 1, January 2017
http://link.springer.com/journal/40273/35/1/page/1

Systematic Review
Challenges in Cost-Effectiveness Analysis Modelling of HPV Vaccines in Low- and Middle-Income Countries: A Systematic Review and Practice Recommendations
Obinna I. Ekwunife, James F. O’Mahony, Andreas Gerber Grote…
Abstract
Background
Low- and middle-income countries (LMICs) face a number of challenges in implementing cervical cancer prevention programmes that do not apply in high-income countries.
Objective
This review assessed how context-specific challenges of implementing cervical cancer prevention strategies in LMICs were accounted for in existing cost-effectiveness analysis (CEA) models of human papillomavirus (HPV) vaccination.
Methods
The databases of MEDLINE, EMBASE, NHS Economic Evaluation Database, EconLit, Web of Science, and the Center for the Evaluation of Value and Risk in Health (CEA) Registry were searched for studies published from 2006 to 2015. A descriptive, narrative, and interpretative synthesis of data was undertaken.
Results
Of the 33 studies included in the review, the majority acknowledged cost per vaccinated girl (CVG) (26 studies) and vaccine coverage rate (21 studies) as particular challenges for LMICs, while nine studies identified screening coverage rate as a challenge. Most of the studies estimated CVG as a composite of different cost items. However, the basis for the items within this composite cost was unclear. The majority used an assumption rather than an observed rate to represent screening and vaccination coverage rates. CVG, vaccine coverage and screening coverage were shown by some studies through sensitivity analyses to reverse the conclusions regarding cost-effectiveness, thereby significantly affecting policy recommendations.
Conclusions
While many studies recognized aspects of the particular challenges of HPV vaccination in LMICs, greater efforts need to be made in adapting models to account for these challenges. These include adapting costings of HPV vaccine delivery from other countries, learning from the outcomes of cervical cancer screening programmes in the same geographical region, and taking into account the country’s previous experience with other vaccination programmes.
Key Points for Decision Makers
:: Cost per vaccinated girl, vaccine coverage and screening coverage are highly uncertain parameters in model-based cost-effectiveness analysis (CEA) of human papillomavirus (HPV) vaccines in low- and middle-income countries.
:: These uncertain parameters matter as they can reverse the conclusions regarding cost-effectiveness made by a CEA, thereby altering the resulting policy choice.
:: More precise parameters could be obtained by adapting costings of HPV vaccine delivery conducted for other countries, observing the outcomes of cervical cancer screening programmes in the same geographical region, and taking into account the country’s previous experience with other vaccination programmes.

PLOS Currents: Disasters

PLOS Currents: Disasters
http://currents.plos.org/disasters/
[Accessed 7 January 2017]

Research Article
Reducing Disaster Exacerbated Non-communicable Diseases Through Public Health Infrastructure Resilience: Perspectives of Australian Disaster Service Providers
December 21, 2016 ·
Background: The exposure of people and infrastructure to flood and storm related disasters across the world is increasing faster than vulnerability is decreasing. For people with non-communicable diseases this presents a significant risk as traditionally the focus of disaster management systems has been on immediate trauma and communicable diseases. This focus must now be expanded to include the management of non-communicable diseases because these conditions are generating the bulk of ill health, disability and premature death around the globe. When public health service infrastructure is destroyed or damaged access to treatment and care is severely jeopardised, resulting in an increased risk of non-communicable disease exacerbation or even death. This research proposes disaster responders, coordinators and government officials are vital assets to mitigate and eventually prevent these problems from being exacerbated during a disaster. This is due to their role in supporting the public health service infrastructure required to maximise treatment and care for people with non-communicable diseases. By focusing on the disaster cycle as a template, and on mitigation and prevention phases in particular, these actions and activities performed by disaster service responders will lead to overall improved preparedness, response, recovery and rehabilitation phases.
Methods: Data were collected via 32 interviews and one focus group (eight participants) between March 2014 and August 2015 (total of 40 participants). The research was conducted in the State of Queensland, Australia, with disaster service providers. The analysis included the phases of: organizing data; data description; data classification; and interpretation.
Results: The research found a relationship between the impact of a disaster on public health service infrastructure, and increased health risks for people with non-communicable diseases. Mitigation strategies were described for all phases of the disaster cycle impacting public health service infrastructure. Specific measures include: increasing the use of telemedicine; preplanning with medical suppliers; effective town planning; health professionals visiting evacuation centers; evacuation centers having power for medical equipment; hubs for treatment and care after a disaster; evacuation of high risk people prior to disaster; mapping people at risk by non-communicable disease; and a mechanism for sharing information between agencies. A common theme from the participants was that having accurate and easily accessible data on people with non-communicable diseases would allow disaster service providers to adequately prepare for and respond to a disaster.
Conclusions: Disaster service providers can play a vital role in reducing the risk of disaster exacerbated non-communicable diseases through public health service infrastructure resilience. They are often employed in communities where disasters occur and are therefore best-placed to lead implementation of the mitigation strategies identified in this research. To sustainably implement the mitigation strategies they will need to become integrated into effective performance and monitoring of the disaster response and health sector during non-disaster periods. For this to occur, the strategies should be integrated into business and strategic plans. Achieving this will help implement the Sendia Framework for Disaster Risk Reduction 2015-2030 and, most importantly, help protect the health of people with non-communicable diseases before, during and after a disaster.

PLoS Currents: Outbreaks

PLoS Currents: Outbreaks
http://currents.plos.org/outbreaks/
[Accessed 7 January 2017]

Research Article
Exploring the Continuum of Vaccine Hesitancy Between African American and White Adults: Results of a Qualitative Study
December 29, 2016 ·
Vaccine delay and refusal present very real threats to public health. Since even a slight reduction in vaccination rates could produce major consequences as herd immunity is eroded, it is imperative to understand the factors that contribute to decision-making about vaccines. Recent scholarship on the concept of “vaccine hesitancy” emphasizes that vaccine behaviors and beliefs tend fall along a continuum from refusal to acceptance. Most research on hesitancy has focused on parental decision-making about childhood vaccines, but could be extended to explore decision-making related to adult immunization against seasonal influenza. In particular, vaccine hesitancy could be a useful approach to understand the persistence of racial/ethnic disparities between African American and White adults. This study relied on a thematic content analysis of qualitative data, including 12 semi-structured interviews, 9 focus groups (N=90), and 16 in-depth interviews, for a total sample of 118 (N=118) African American and White adults. All data were transcribed and analyzed with Atlas.ti. A coding scheme combining both inductive and deductive codes was utilized to identify themes related to vaccine hesitancy. The study found a continuum of vaccine behavior from never-takers, sometimes-takers, and always-takers, with significant differences between African Americans and Whites.  We compared our findings to the Three Cs: Complacency, Convenience, and Confidence framework. Complacency contributed to low vaccine acceptance with both races.  Among sometimes-takers and always-takers, convenience was often cited as a reason for their behavior, while never-takers of both races were more likely to describe other reasons for non-vaccination, with convenience only a secondary explanation.  However, for African Americans, cost was a barrier.  There were racial differences in trust and confidence that impacted the decision-making process. The framework, though not a natural fit for the data, does provide some insight into the differential sources of hesitancy between these two populations. Complacency and confidence clearly impact vaccine behavior, often more profoundly than convenience, which can contribute either negatively or positively to vaccine acceptance. The Three Cs framework is a useful, but limited tool to understanding racial disparities. Understanding the distinctions in those cultural factors that drive lower vaccine confidence and greater hesitancy among African Americans could lead to more effective communication strategies as well as changes in the delivery of vaccines to increase convenience and passive acceptance.

PLoS Medicine

PLoS Medicine
http://www.plosmedicine.org/
(Accessed 7 January 2017)

Research Article
Zika Virus Infection as a Cause of Congenital Brain Abnormalities and Guillain–Barré Syndrome: Systematic Review
Fabienne Krauer, Maurane Riesen, Ludovic Reveiz, Olufemi T. Oladapo, Ruth Martínez-Vega, Teegwendé V. Porgo, Anina Haefliger, Nathalie J. Broutet, Nicola Low, WHO Zika Causality Working Group
| published 03 Jan 2017 PLOS Medicine
http://dx.doi.org/10.1371/journal.pmed.1002203

Research Article
Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model
Emily A. Kendall, Sourya Shrestha, Ted Cohen, Eric Nuermberger, Kelly E. Dooley, Lice Gonzalez-Angulo, Gavin J. Churchyard, Payam Nahid, Michael L. Rich, Cathy Bansbach, Thomas Forissier, Christian Lienhardt, David W. Dowdy
| published 03 Jan 2017 PLOS Medicine
http://dx.doi.org/10.1371/journal.pmed.1002202

PLoS One

PLoS One
http://www.plosone.org/
[Accessed 7 January 2017]

Research Article
Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis
Gerhard Falkenhorst, Cornelius Remschmidt, Thomas Harder, Eva Hummers-Pradier, Ole Wichmann, Christian Bogdan
Research Article | published 06 Jan 2017 PLOS ONE
http://dx.doi.org/10.1371/journal.pone.0169368

Research Article
Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Clinical and Hypoxemic Childhood Pneumonia over Three Years in Central Malawi: An Observational Study
Eric D. McCollum, Bejoy Nambiar, Rashid Deula, Beatiwel Zadutsa, Austin Bondo, Carina King, James Beard, Harry Liyaya, Limangeni Mankhambo, Marzia Lazzerini, Charles Makwenda, Gibson Masache, Naor Bar-Zeev, Peter N. Kazembe, Charles Mwansambo, Norman Lufesi, Anthony Costello, Ben Armstrong, Tim Colbourn
Research Article | published 04 Jan 2017 PLOS ONE
http://dx.doi.org/10.1371/journal.pone.0168209

Research Article
Potential Cost-Effectiveness of an Influenza Vaccination Program Offering Microneedle Patch for Vaccine Delivery in Children
Carlos Wong, Minghuan Jiang, Joyce H. S. You
Research Article | published 22 Dec 2016 PLOS ONE
http://dx.doi.org/10.1371/journal.pone.0169030

PLoS Pathogens

PLoS Pathogens
http://journals.plos.org/plospathogens/

Research Article
Detection of Viral RNA in Tissues following Plasma Clearance from an Ebola Virus Infected Patient
Mirella Biava, Claudia Caglioti , Licia Bordi, Concetta Castilletti, Francesca Colavita, Serena Quartu, Emanuele Nicastri, Francesco Nicola Lauria, Nicola Petrosillo, Simone Lanini, Thomas Hoenen, Gary Kobinger, Alimuddin Zumla,  [ … ], Eleonora Lalle
Published: January 5, 2017
http://dx.doi.org/10.1371/journal.ppat.1006065
Abstract
An unprecedented Ebola virus (EBOV) epidemic occurred in 2013–2016 in West Africa. Over this time the epidemic exponentially grew and moved to Europe and North America, with several imported cases and many Health Care Workers (HCW) infected. Better understanding of EBOV infection patterns in different body compartments is mandatory to develop new countermeasures, as well as to fully comprehend the pathways of human-to-human transmission. We have longitudinally explored the persistence of EBOV-specific negative sense genomic RNA (neg-RNA) and the presence of positive sense RNA (pos-RNA), including both replication intermediate (antigenomic-RNA) and messenger RNA (mRNA) molecules, in the upper and lower respiratory tract, as compared to plasma, in a HCW infected with EBOV in Sierra Leone, who was hospitalized in the high isolation facility of the National Institute for Infectious Diseases “Lazzaro Spallanzani” (INMI), Rome, Italy. We observed persistence of pos-RNA and neg-RNAs in longitudinally collected specimens of the lower respiratory tract, even after viral clearance from plasma, suggesting possible local replication. The purpose of the present study is to enhance the knowledge on the biological features of EBOV that can contribute to the human-to-human transmissibility and to develop effective intervention strategies. However, further investigation is needed in order to better understand the clinical meaning of viral replication and shedding in the respiratory tract.
Author Summary
An unprecedented Ebola outbreak occurred in 2013–2016 in West Africa. In order to better understand EBOV infection patterns in different body compartments, we have longitudinally explored the presence of already assessed markers of ongoing EBOV replication (negative sense genomic RNA and positive sense RNA) in the upper and lower respiratory tract, as compared to plasma and other body compartments, in a Health Care Worker infected with EBOV in Sierra Leone, who was hospitalized in the high isolation facility of the National Institute for Infectious Diseases “Lazzaro Spallanzani” (INMI), Rome, Italy. The presence of total EBOV RNA and replication markers was observed in specimens of the lower respiratory tract, even after viral clearance from plasma, suggesting possible local replication. Our results contribute to the knowledge on the biological features of EBOV and shed light on the potential role of respiratory compartment in human-to-human transmissibility.

Research Matters
The Importance of International Collaborations to Advance Research Endeavors
Alfredo G. Torres
| published 05 Jan 2017 PLOS Pathogens
http://dx.doi.org/10.1371/journal.ppat.1006047

Public Health Reports – Volume 132, Issue 1, January/February 2017

Public Health Reports
Volume 132, Issue 1, January/February 2017
http://phr.sagepub.com/content/current

Research
Infectious Disease Hospitalizations Among American Indian/Alaska Native and Non–American Indian/Alaska Native Persons in Alaska, 2010-2011
First Published December 9, 2016; pp. 65–75
Prabhu P. Gounder, Robert C. Holman, Sara M. Seeman, Alice J. Rarig, Mary McEwen, Claudia A. Steiner, Michael L. Bartholomew, Thomas W. Hennessy
Abstract
Objective:
Reports about infectious disease (ID) hospitalization rates among American Indian/Alaska Native (AI/AN) persons have been constrained by data limited to the tribal health care system and by comparisons with the general US population. We used a merged state database to determine ID hospitalization rates in Alaska.
Methods:
We combined 2010 and 2011 hospital discharge data from the Indian Health Service and the Alaska State Inpatient Database. We used the merged data set to calculate average annual age-adjusted and age-specific ID hospitalization rates for AI/AN and non-AI/AN persons in Alaska. We stratified the ID hospitalization rates by sex, age, and ID diagnosis.
Results:
ID diagnoses accounted for 19% (6501 of 34 160) of AI/AN hospitalizations, compared with 12% (7397 of 62 059) of non-AI/AN hospitalizations. The average annual age-adjusted hospitalization rate was >3 times higher for AI/AN persons (2697 per 100 000 population) than for non-AI/AN persons (730 per 100 000 population; rate ratio = 3.7, P < .001). Lower respiratory tract infection (LRTI), which occurred in 38% (2486 of 6501) of AI/AN persons, was the most common reason for ID hospitalization. AI/AN persons were significantly more likely than non-AI/AN persons to be hospitalized for LRTI (rate ratio = 5.2, P < .001).
Conclusions:
A substantial disparity in ID hospitalization rates exists between AI/AN and non-AI/AN persons, and the most common reason for ID hospitalization among AI/AN persons was LRTI. Public health programs and policies that address the risk factors for LRTI are likely to benefit AI/AN persons.

Science Translational Medicine – 04 January 2017 Vol 9, Issue 371

Science Translational Medicine
04 January 2017 Vol 9, Issue 371
http://stm.sciencemag.org/

Research Article
Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects
By James G. Kublin, Sebastian A. Mikolajczak, Brandon K. Sack, Matt E. Fishbaugher, Annette Seilie, Lisa Shelton, Tracie VonGoedert, Melike Firat, Sara Magee, Emma Fritzen, Will Betz, Heather S. Kain, Dorender A. Dankwa, Ryan W. J. Steel, Ashley M. Vaughan, D. Noah Sather, Sean C. Murphy, Stefan H. I. Kappe
Science Translational Medicine04 Jan 2017 Restricted Access
A triple punch knocks out the malaria parasite
Vaccination with weakened infectious forms of the malaria parasite is the most promising approach to protect against malaria infection. However, creating genetically defined and weakened parasite strains that are safe for vaccination remains challenging. In a new study, Kublin et al. show that genetic engineering of the malaria parasite by the precise removal of three genes creates a parasite strain that infects humans and is well tolerated but cannot cause malaria. These genetically attenuated parasites thus appear safe for vaccination and stimulate the human immune system to generate responses that have the potential to block infection.
Abstract
Immunization of humans with whole sporozoites confers complete, sterilizing immunity against malaria infection. However, achieving consistent safety while maintaining immunogenicity of whole parasite vaccines remains a formidable challenge. We generated a genetically attenuated Plasmodium falciparum (Pf) malaria parasite by deleting three genes expressed in the pre-erythrocytic stage (Pf p52−/p36−/sap1−). We then tested the safety and immunogenicity of the genetically engineered (Pf GAP3KO) sporozoites in human volunteers. Pf GAP3KO sporozoites were delivered to 10 volunteers using infected mosquito bites with a single exposure consisting of 150 to 200 bites per subject. All subjects remained blood stage–negative and developed inhibitory antibodies to sporozoites. GAP3KO rodent malaria parasites engendered complete, protracted immunity against infectious sporozoite challenge in mice. The results warrant further clinical testing of Pf GAP3KO and its potential development into a vaccine strain.

Social Science & Medicine – Volume 171, Pages 1-102 (December 2016)

Social Science & Medicine
Volume 171, Pages 1-102 (December 2016)
http://www.sciencedirect.com/science/journal/02779536/170

Regular articles
Standardizing psycho-medical torture during the War on Terror: Why it happened, how it happened, and why it didn’t work
Original Research Article
Pages 1-8
Myles Balfe
Abstract
After 9/11/2001 the United States launched a global War on Terror. As part of this War, terrorism suspects were detained by the U.S. military and by the C.I.A. It is now widely recognized that the United States tortured a number of these detainees in the context of its ‘enhanced interrogation’ programme. This article examines how and why U.S. organizations developed standards that allowed healthcare professionals to become involved in torture; why the standards developed by U.S. security institutions failed to control the actions of enhanced interrogation personnel on the ground; and what the role of standards were in stopping the enhanced interrogation initiative. The article concludes by discussing the general lessons that the enhanced interrogation programme has for social science research on standards, namely that individuals can experience ambivalence when caught between competing organizational and professional standards and that it might be inherently difficult to successfully enact certain protocols when these relate to deviant or destructive acts.

Tropical Medicine & International Health – January 2017 Volume 22, Issue 1 Pages 1–121

Tropical Medicine & International Health
January 2017 Volume 22, Issue 1 Pages 1–121
http://onlinelibrary.wiley.com/doi/10.1111/tmi.2017.22.issue-1/issuetoc

Original Research Papers
Household experience and costs of seeking measles vaccination in rural Guinea-Bissau (pages 12–20)
S. Byberg, A. B. Fisker, A. Rodrigues, I. Balde, U. Enemark, P. Aaby, C. S. Benn and U. K. Griffiths
Version of Record online: 28 OCT 2016 | DOI: 10.1111/tmi.12793

Tropical Medicine & International Health – January 2017 Volume 22, Issue 1 Pages 1–121

Tropical Medicine & International Health
January 2017 Volume 22, Issue 1 Pages 1–121
http://onlinelibrary.wiley.com/doi/10.1111/tmi.2017.22.issue-1/issuetoc

Original Research Papers
Human papillomavirus (HPV) awareness and vaccine receptivity among Senegalese adolescents (pages 113–121)
Philip M. Massey, Ruth K. Boansi, Jessica D. Gipson, Rachel M. Adams, Helene Riess, Thierno Dieng, Michael L. Prelip and Deborah C. Glik
Version of Record online: 14 NOV 2016 | DOI: 10.1111/tmi.12798

Vaccine – Volume 35, Issue 1, Pages 1-200 (3 January 2017)

Vaccine
Volume 35, Issue 1, Pages 1-200 (3 January 2017)
http://www.sciencedirect.com/science/journal/0264410X/35/1

A general measles vaccination campaign in urban Guinea-Bissau: Comparing child mortality among participants and non-participants
Original Research Article
Pages 33-39
S. Byberg, S.M. Thysen, A. Rodrigues, C. Martins, C. Cabral, M. Careme, P. Aaby, C.S. Benn, A.B. Fisker
Abstract
Background
Measles vaccination campaigns targeting children aged 9–59 months are conducted every three years in Guinea-Bissau. Studies have demonstrated beneficial non-specific effects of measles vaccine. We compared mortality one year after the December 2012 measles vaccination campaign in Bissau city for children who received campaign measles vaccine with children who did not receive campaign measles vaccine.
Methods
Field workers from Bandim Health Project registered all children living in the Bandim Health Project’s study area who received measles vaccination at the campaign posts. Children not seen during the campaign were visited at home and campaign participation status was assessed. We compared mortality rates of participants vs. non-participants in Cox regression models.
Results
5633 children aged 9–59 months (85%) received campaign measles vaccination and 1006 (15%) did not. During the subsequent year 16 children died. Adjusted for background factors, the hazard ratio (HR) comparing measles vaccinated versus unvaccinated was 0.28 (95% CI: 0.10–0.77). The benefit was larger for girls (HR: 0.17 (0.05–0.59)) and for children who had received routine measles vaccine before the campaign (HR: 0.15 (0.04–0.63)).
Conclusions
We found indications of strong beneficial non-specific effects of receiving measles vaccine during the 2012 campaign, especially for girls and children with previous routine measles vaccination. Measles vaccination campaigns may be an effective way of improving child survival.

Vaccine – Volume 35, Issue 1, Pages 1-200 (3 January 2017)

Vaccine
Volume 35, Issue 1, Pages 1-200 (3 January 2017)
http://www.sciencedirect.com/science/journal/0264410X/35/1

Country specific predictions of the cost-effectiveness of malaria vaccine RTS,S/AS01 in endemic Africa
Original Research Article
Pages 53-60
Katya Galactionova, Fabrizio Tediosi, Flavia Camponovo, Thomas A. Smith, Peter W. Gething, Melissa A. Penny
Abstract
Background
RTS,S/AS01 is a safe and moderately efficacious vaccine considered for implementation in endemic Africa. Model predictions of impact and cost-effectiveness of this new intervention could aid in country adoption decisions.
Methods
The impact of RTS,S was assessed in 43 countries using an ensemble of models of Plasmodium falciparum epidemiology. Informed by the 32 months follow-up data from the phase 3 trial, vaccine effectiveness was evaluated at country levels of malaria parasite prevalence, coverage of control interventions and immunization. Benefits and costs of the program incremental to routine malaria control were evaluated for a four dose schedule: first dose administered at six months, second and third – before 9 months, and fourth dose at 27 months of age. Sensitivity analyses around vaccine properties, transmission, and economic inputs were conducted.
Results
If implemented in all 43 countries the vaccine has the potential to avert 123 (117; 129) million malaria episodes over the first 10 years. Burden averted averages 18,413 (range of country median estimates 156–40,054) DALYs per 100,000 fully vaccinated children with much variation across settings primarily driven by differences in transmission intensity. At a price of $5 per dose program costs average $39.8 per fully vaccinated child with a median cost-effectiveness ratio of $188 (range $78–$22,448) per DALY averted; the ratio is lower by one third – $136 (range $116–$220) – in settings where parasite prevalence in children aged 2–10 years is at or above 10%.
Conclusion
RTS,S/AS01 has the potential to substantially reduce malaria burden in children across Africa. Conditional on assumptions on price, coverage, and vaccine properties, adding RTS,S to routine malaria control interventions would be highly cost-effective. Implementation decisions will need to further consider feasibility of scaling up existing control programs, and operational constraints in reaching children at risk with the schedule.

Vaccine – Volume 35, Issue 1, Pages 1-200 (3 January 2017)

Vaccine
Volume 35, Issue 1, Pages 1-200 (3 January 2017)
http://www.sciencedirect.com/science/journal/0264410X/35/1

Vaccination against hepatitis B virus among people who inject drugs – A 20 year experience from a Swedish needle exchange program
Original Research Article
Pages 84-90
M. Alanko Blomé, P. Björkman, L. Flamholc, H. Jacobsson, A. Widell
Abstract
Background
People who inject drugs (PWID) are at particular risk of hepatitis B virus (HBV) acquisition, but often have poor access or adherence to HBV vaccination. Vaccination against HBV has been offered at a major Swedish needle exchange program (NEP) since 1994. The aim of this study was to evaluate vaccine completion and response rates, and the effect of sequential booster doses to non-responders to the standard vaccination schedule.
Methods
PWID enrolled in the NEP 1994–2013, without serological markers for HBV at baseline (negative for HBsAg/anti-HBc/anti-HBs), were offered a three-dose standard intramuscular vaccination schedule (Engerix®-B, GSK, 20 μg/mL, intended to be received at months 0, 1 and 6). Vaccination response was defined as protective levels of anti-HBs (⩾10 mIU/mL). Up to three booster doses were then offered for non-responders, each followed by anti-HBs testing.
Results
HBV data was available for 2352 identifiable individuals at NEP enrolment, of whom 1516 (64.5%) had no markers for previous HBV exposure or vaccination. Vaccination was initiated for 1142 (75.3%) individuals and 898 (59.2%) completed the standard vaccination schedule. Post-vaccination anti-HBs levels were available from 800 individuals, with 598 (74.8%) responding to the basic vaccination schedule. After up to three booster doses a total of 676 (84.5%) individuals achieved protective anti-HBs levels. Non-response to vaccination was associated with higher age and anti-HCV positivity (p < 0.001). Eighteen incident cases of HBV infection were observed among vaccine non-responders, as well as 30 cases among those who had not completed vaccination.
Conclusion
We demonstrate the feasibility of including HBV vaccination in the services offered by a NEP, with completion of vaccination in a majority of HBV-susceptible PWID. The response to HBV vaccination among PWID was relatively low; however, the addition of up to three booster doses improved the response rate from 74.8 to 84.5%.

Vaccine – Volume 35, Issue 1, Pages 1-200 (3 January 2017)

Vaccine
Volume 35, Issue 1, Pages 1-200 (3 January 2017)
http://www.sciencedirect.com/science/journal/0264410X/35/1

Improving adolescent HPV vaccination in a randomized controlled cluster trial using the 4 Pillars™ practice Transformation Program
Original Research Article
Pages 109-117
Richard K. Zimmerman, Krissy K. Moehling, Chyongchiou J. Lin, Song Zhang, Jonathan M. Raviotta, Evelyn C. Reis, Sharon G. Humiston, Mary Patricia Nowalk
Abstract
Objective
Uptake of meningococcal vaccine (MCV) and tetanus, diphtheria and pertussis (Tdap) vaccine among adolescents has approached Healthy People 2020 goals, but human papillomavirus (HPV) vaccination has not. This study evaluated an intervention using the 4 Pillars™ Practice Transformation Program to increase HPV, MCV and Tdap uptake among adolescents in primary care practices.
Methods
Practices with at least 50 patients 11–17 years old with estimated vaccination rates less than national goals, were assigned to intervention (n = 11) and control (n = 11) groups in a randomized controlled cluster trial; 9 intervention and 11 control sites completed the study. The baseline and active study periods were 7/1/2013–6/30/2014 and 7/1/2014–3/31/2015, respectively. Vaccination and demographic data for patients who had a visit in both study periods were derived from de-identified EMR extractions. Primary outcomes were vaccination rates and percentage point (PP) changes. Data were analyzed in 2015–16.
Results
Among the cohort of 10,861 adolescent patients, 38% were 11–13 years old; 50% were female; 18% were non-white; and 64% were commercially insured. Average baseline HPV initiation rates were 52.5% for intervention and 61.8% for control groups. After 9 months, the intervention sites increased HPV initiation 10.2 PP compared with 7.3 PP in control sites (P < 0.001); HPV series completion rates did not differ between groups. Implementation of >10 strategies to improve rates significantly increased the likelihood of HPV series initiation (OR = 2.06, 95% CI = 1.43, 2.96).
Conclusions
Using >10 strategies from the 4 Pillars™ Practice Transformation Program is effective for increasing HPV series initiation among adolescents.
Clinical trial registry number: NCT02165722.

Vaccine – Volume 35, Issue 1, Pages 1-200 (3 January 2017)

Vaccine
Volume 35, Issue 1, Pages 1-200 (3 January 2017)
http://www.sciencedirect.com/science/journal/0264410X/35/1

Clinician knowledge, clinician barriers, and perceived parental barriers regarding human papillomavirus vaccination: Association with initiation and completion rates
Original Research Article
Pages 164-169
Lila J. Finney Rutten, Jennifer L. St. Sauver, Timothy J. Beebe, Patrick M. Wilson, Debra J. Jacobson, Chun Fan, Carmen Radecki Breitkopf, Susan T. Vadaparampil, Robert M. Jacobson
Abstract
Purpose
We tested the hypothesis that clinician knowledge, clinician barriers, and perceived parental barriers relevant to the human papillomavirus (HPV) vaccination account for the variation in vaccine delivery at the practice-site level.
Methods
We conducted a survey from October 2015 through January 2016 among primary care clinicians (n = 280) in a 27-county geographic region to assess clinician knowledge, clinician barriers, and perceived parental barriers regarding HPV vaccination. Primary care clinicians included family medicine physicians, general pediatricians, and family and pediatric nurse-practitioners. We also used the Rochester Epidemiology Project to measure HPV vaccination delivery. Specifically we used administrative data to measure receipt of at least one valid HPV vaccine dose (initiation) and receipt of three valid HPV vaccine doses (completion) among 9–18 year old patients residing in the same 27-county geographic region. We assessed associations of clinician survey data with variation in vaccine delivery at the clinical site using administrative data on patients aged 9–18 years (n = 68,272).
Results
Consistent with our hypothesis, we found that greater knowledge of HPV and the HPV vaccination was associated with higher rates of HPV vaccination initiation (Incidence rate ratio [IRR] = 1.05) and completion of three doses (IRR = 1.28). We also found support for the hypothesis that greater perceived parental barriers to the HPV vaccination were associated with lower rates of initiation (IRR = 0.94) and completion (IRR = 0.90). These IRRs were statistically significant even after adjustment for site-level characteristics including percent white, percent female, percent ages 9–13, and percent with government insurance or self-pay at each site.
Conclusions
Clinician knowledge and their report of the frequency of experiencing parental barriers are associated with HPV vaccine delivery rates—initiation and completion. Higher measures of knowledge correlated with higher rates. Fewer perceived occurrences of parental barriers correlated with lower rates. These data can guide efforts to improve HPV vaccine delivery in clinical settings.

Vaccine – Volume 35, Issue 1, Pages 1-200 (3 January 2017)

Vaccine
Volume 35, Issue 1, Pages 1-200 (3 January 2017)
http://www.sciencedirect.com/science/journal/0264410X/35/1

Age-specific effectiveness following each dose of acellular pertussis vaccine among infants and children in New Zealand
Original Research Article
Pages 177-183
Sarah Radke, Helen Petousis-Harris, Donna Watson, Dudley Gentles, Nikki Turner
Abstract
Background
Though it is believed the switch from whole cell to acellular pertussis vaccine has contributed to the resurgence of pertussis disease, few studies have evaluated vaccine effectiveness (VE) and duration of protection provided by an acellular vaccine schedule including three primary doses but no toddler-age dose. We assessed this schedule in New Zealand (NZ), a setting with historically high rates of pertussis disease, and low but recently improved immunisation coverage. We further evaluated protection following the preschool-age booster dose.
Methods
We performed a nested case-control study using national-level healthcare data. Hospitalised and non-hospitalised pertussis was detected among children 6 weeks to 7 years of age between January 2006 and December 2013. The NZ National Immunisation Register provided vaccination status for cases and controls. Conditional logistic regression was used to calculate dose-specific VE with duration of immunity examined by stratifying VE into ages aligned with the immunisation schedule.
Results
VE against pertussis hospitalisation was 93% (95% confidence interval [CI]: 87, 96) following three doses among infants aged 5–11 months who received three compared to zero doses. This protection was sustained through children’s fourth birthdays (VE ⩾ 91%). VE against non-hospitalised pertussis was also sustained after three doses, from 86% (95% CI: 80, 90) among 5–11 month olds to 84% (95% CI: 80, 88) among 3-year-olds. Following the first booster dose at 4 years of age, the protective VE of 93% (95% CI: 90, 95) among 4-year-olds continued through 7 years of age (VE ⩾ 91%).
Conclusions
We found a high level of protection with no reduction in VE following both the primary course and the first booster dose. These findings support a 3-dose primary course of acellular vaccine with no booster dose until 4 years of age.